115 related articles for article (PubMed ID: 3450455)
1. Effect of bromocriptine on LH pulsatility in the polycystic ovary syndrome.
Chapman AJ; Wilson MD; Obhrai M; Sawers RS; Lynch SS; Royston JP; Clayton RN
Clin Endocrinol (Oxf); 1987 Nov; 27(5):571-80. PubMed ID: 3450455
[TBL] [Abstract][Full Text] [Related]
2. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
[TBL] [Abstract][Full Text] [Related]
3. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome.
Berga SL; Yen SS
Clin Endocrinol (Oxf); 1989 Feb; 30(2):177-84. PubMed ID: 2532984
[TBL] [Abstract][Full Text] [Related]
4. Role of progesterone deficiency in the development of luteinizing hormone and androgen abnormalities in polycystic ovary syndrome.
Fiad TM; Cunningham SK; McKenna TJ
Eur J Endocrinol; 1996 Sep; 135(3):335-9. PubMed ID: 8890725
[TBL] [Abstract][Full Text] [Related]
5. The effect of bromocriptine in the polycystic ovary syndrome.
Spruce BA; Kendall-Taylor P; Dunlop W; Anderson AJ; Watson MJ; Cook DB; Gray C
Clin Endocrinol (Oxf); 1984 Apr; 20(4):481-8. PubMed ID: 6424978
[TBL] [Abstract][Full Text] [Related]
6. [Comprehensive approach to clinical background and effect of bromocriptine administration in patients with endocrinological polycystic ovarian disease].
Aisaka K; Kaneda S; Tsuzuki H; Tawada T; Kokuho K; Toriya Y; Nojima M; Yoshida K; Mori H
Nihon Naibunpi Gakkai Zasshi; 1990 Feb; 66(2):101-12. PubMed ID: 2332079
[TBL] [Abstract][Full Text] [Related]
7. A double blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovary syndrome.
Buvat J; Buvat-Herbaut M; Marcolin G; Racadot A; Fourlinnie JC; Beuscart R; Fossati P
J Clin Endocrinol Metab; 1986 Jul; 63(1):119-24. PubMed ID: 3519644
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
[TBL] [Abstract][Full Text] [Related]
9. Relationship of GnRH-stimulated LH release to episodic LH secretion and baseline endocrine-metabolic measures in women with polycystic ovary syndrome.
Patel K; Coffler MS; Dahan MH; Malcom PJ; Deutsch R; Chang RJ
Clin Endocrinol (Oxf); 2004 Jan; 60(1):67-74. PubMed ID: 14678290
[TBL] [Abstract][Full Text] [Related]
10. Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome.
Venturoli S; Porcu E; Fabbri R; Magrini O; Gammi L; Paradisi R; Forcacci M; Bolzani R; Flamigni C
Clin Endocrinol (Oxf); 1988 Jan; 28(1):93-107. PubMed ID: 3139335
[TBL] [Abstract][Full Text] [Related]
11. Augmented frequency and mass of LH discharged per burst are accompanied by marked disorderliness of LH secretion in adolescents with polycystic ovary syndrome.
García-Rudaz MC; Ropelato MG; Escobar ME; Veldhuis JD; Barontini M
Eur J Endocrinol; 1998 Dec; 139(6):621-30. PubMed ID: 9916868
[TBL] [Abstract][Full Text] [Related]
12. [Effects of bromocriptine on endocrine environment in the polycystic ovary syndrome].
Huang HJ; Ishimaru T; Yamabe T
Nihon Naibunpi Gakkai Zasshi; 1988 Apr; 64(4):265-78. PubMed ID: 3136040
[TBL] [Abstract][Full Text] [Related]
13. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
Veldhuis JD; Pincus SM; Garcia-Rudaz MC; Ropelato MG; Escobar ME; Barontini M
J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
[TBL] [Abstract][Full Text] [Related]
14. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
15. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
Christman GM; Randolph JF; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
[TBL] [Abstract][Full Text] [Related]
16. Dopamine might not be involved in the pathogenesis of polycystic ovary syndrome.
Ferriani RA; Silva de Sá MF; Moura MD; Moreira AC; Gomes UA
Gynecol Endocrinol; 1989 Dec; 3(4):317-27. PubMed ID: 2516707
[TBL] [Abstract][Full Text] [Related]
17. Acute effects of bromocriptine on gonadotropin secretion in polycystic ovary syndrome.
Buvat J; Buvat-Herbaut M; Marcolin G; Racadot A; Fourlinnie JC; Fossati P
Fertil Steril; 1985 Sep; 44(3):356-60. PubMed ID: 3161758
[TBL] [Abstract][Full Text] [Related]
18. Bromocriptine treatment of women with clomiphene-resistant polycystic ovary syndrome.
Polson DW; Mason HD; Franks S
Clin Endocrinol (Oxf); 1987 Feb; 26(2):197-203. PubMed ID: 3117444
[TBL] [Abstract][Full Text] [Related]
19. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine.
Sauder SE; Frager M; Case GD; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1984 Nov; 59(5):941-8. PubMed ID: 6434588
[TBL] [Abstract][Full Text] [Related]
20. The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovarian disease.
Steingold KA; Lobo RA; Judd HL; Lu JK; Chang RJ
J Clin Endocrinol Metab; 1986 May; 62(5):1048-51. PubMed ID: 2937800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
